SGM-101

SGM-101 is a fluorescent monoclonal antibody that binds CEA, a protein sitting on the surface of most colorectal tumor cells [1]. Injected intravenously a few days before surgery, the drug accumulates in tumor tissue. During the operation, the surgeon switches on a near-infrared camera and cancerous tissue glows bright against surrounding healthy tissue [2]. Standard 'white light' visualization misses small tumor deposits, positive margins, and occult peritoneal or hepatic metastases that look identical to normal tissue. In colorectal cancer, incomplete resection of locally advanced or recurrent disease is the single biggest predictor of relapse, and reoperation rates for positive margins remain a real problem in rectal surgery. Surgimab, a French company spun out from the Institut du Cancer de Montpellier, is running the Phase 3 trial NCT03659448 in patients undergoing surgery for primary or recurrent colorectal cancer, comparing SGM-101 plus standard visualization against standard visualization alone [6]. The primary endpoint is histopathology-confirmed tumor detection at the surgical bed. If the trial reads out positive, SGM-101 could become the first CEA-targeted intraoperative imaging agent approved for colorectal surgery.

SGM-101 is not FDA approved and is not commercially available. Surgimab has not filed a BLA (biologics license application, the FDA submission required for biologic drugs). The current regulatory position is investigational, with the Phase 3 trial NCT03659448 recruiting 300 patients across European and US centers [6]. The trial started in June 2019 with a prior publicly listed study completion estimate of December 2024. As of mid-2026 the study is still enrolling, meaning the readout has slipped by at least 18 months and is now most plausibly a 2027 event with mature follow-up data reading out in 2028. Eight years of enrollment for a 300-patient surgical imaging trial is a real red flag: it reflects some combination of COVID-era site disruption, slow US site activation, and the operational difficulty of coordinating pre-op infusion logistics at academic surgical centers. Investors should treat any near-term catalyst framing skeptically until Surgimab publicly refreshes the timeline. The primary endpoint is surgical resection histopathology, meaning the trial reads out based on whether tissue flagged by SGM-101 as tumor actually contains tumor when pathologists examine it. Surgimab is sponsoring the study directly rather than partnering with a larger imaging or oncology company, which keeps the commercial upside concentrated but limits the promotional muscle behind an eventual launch. The company has additional studies open in pancreatic cancer (NCT05984810, Leiden University), a completed Phase 1 in lung cancer (NCT04315467, Penn), and a peritoneal carcinomatosis feasibility study (NCT02784028, ICM Montpellier) [7][8][9]. In the United States, intraoperative fluorescence imaging agents are regulated as drugs by CDER, not as devices, because the imaging agent itself is administered systemically. That means SGM-101 will need a full BLA rather than a 510(k) clearance. No CMS coverage determination exists. Reimbursement for intraoperative imaging agents in colorectal surgery remains unresolved, and Surgimab would need to work with CMS and commercial payers to establish a permanent HCPCS code (Healthcare Common Procedure Coding System, the standardized billing code insurers use to identify a specific product or service) post-approval, most likely a permanent J-code (the HCPCS subcategory reserved for injectable drugs, required for hospital reimbursement). In Europe, SGM-101 will follow the drug pathway through the EMA rather than a CE mark under EU MDR, because the fluorescent antibody is a systemically administered biologic rather than a device. Public disclosures do not confirm an active EMA marketing authorization application, and no European approval has been granted. Surgimab is French and much of the Phase 3 activity centers on French, Dutch, and other European sites, so a first commercial launch in France or the Netherlands via the EMA centralized procedure is the more likely near-term pathway, followed by country-by-country reimbursement negotiations with national health-technology assessment bodies (HAS in France, ZIN in the Netherlands, NICE in the UK). The NIR camera systems used to visualize the SGM-101 signal are regulated separately as medical devices under EU MDR and already carry CE marks through third-party vendors (Stryker, Olympus, Karl Storz).

SGM-101 is a full-length monoclonal antibody against CEACAM5 (better known as CEA), chemically conjugated to a near-infrared fluorescent dye that emits light around 700 nm [1]. CEA is the classic tumor marker in colorectal cancer, a cell surface protein normally expressed at low levels in adult epithelium but massively upregulated in most colorectal, pancreatic, and some lung tumors [13]. On colorectal adenocarcinoma, CEA sits on the outside of tumor cells at densities orders of magnitude higher than in surrounding stromal or muscle tissue, giving a clean signal-to-background ratio when the labeled antibody accumulates [13]. The workflow: the patient receives an intravenous infusion 2 to 4 days before surgery, the antibody circulates and binds CEA on tumor cells, unbound antibody clears from healthy tissue, and during the operation the surgeon uses a NIR-capable camera system to visualize the fluorescent signal in real time overlaid on the standard surgical view. Because NIR light penetrates several millimeters into tissue, the technology can identify small tumor deposits below the visible surface. The Phase 1 dose-finding study established 10 mg as the optimal dose, with tumor-to-background ratios (TBR, the ratio of fluorescence intensity in tumor tissue vs adjacent normal tissue) in the 1.7 to 2.4 range across colorectal indications [1]. Note that TBR is a surrogate imaging metric, not classical diagnostic sensitivity or specificity: the pivotal Phase 3 endpoint of histopathology-confirmed detection will produce the first properly powered sensitivity/specificity readout for the agent. Specificity depends on CEA expression: at the strong-overexpression cutoffs relevant for reliable intraoperative imaging, roughly 10 to 30% of colorectal cases may not generate sufficient signal, even though large tissue-microarray series find nearly universal CEA positivity (about 98.7%) in CRC at the most permissive IHC cutoff [14]. A recent CRC liver-metastasis imaging-target study found CEACAM5 relative-positive expression in about 79% of samples using an imaging-relevant cutoff [18]. Patient selection by pre-operative serum CEA or biopsy-confirmed overexpression may be required in future labeling.

The evidence base is small but internally consistent. The first-in-human safety and effectiveness study by Boonstra et al. treated 26 colorectal cancer patients (9 dose-escalation, 17 expansion) with escalating SGM-101 doses and reported no treatment-related serious adverse events, three possibly related mild adverse events in the dose-escalation cohort, and no changes in vital signs, ECG, or laboratory results after the 10 mg dose. No infusion reactions requiring intervention and no clinically significant immunogenicity signal were reported in this cohort [15]. The follow-on Phase 1 dose-finding study by de Valk et al. confirmed 10 mg as the imaging-optimal dose and demonstrated clear fluorescence signal in tumor tissue with TBRs of 1.7 to 2.4 [1]. A separate study in 18 patients with peritoneal carcinomatosis (widespread cancer nodules seeded across the abdominal lining) from CEA-overexpressing digestive cancers showed SGM-101 could identify additional tumor deposits during cytoreductive surgery and HIPEC (hyperthermic intraperitoneal chemotherapy, a procedure that bathes the abdomen in heated chemotherapy after visible tumors are removed), a setting where finding every metastasis matters more than in almost any other operation [2]. More recent data from Dutch and US groups extended the tool to colorectal lung metastases and locally advanced rectal cancer. Warmerdam et al. (2025) reported long-term local control outcomes after CEA-targeted fluorescence-guided surgery in locally advanced and recurrent rectal cancer, a setting where positive margin rates historically run 15 to 25% [3]. Meijer et al. (2024) showed feasibility of SGM-101 for identifying colorectal lung metastases, and Azari et al. published a nonrandomized JAMA Network Open study of CEA-targeted NIR imaging in lung cancer [4][5]. All of this is analytical validity and small-scale clinical utility, not the randomized outcomes evidence that surgeons and payers actually want. The Phase 3 trial NCT03659448 is designed to fill that gap by tying fluorescence-detected tumor to histopathology-confirmed disease in a properly sized cohort [6]. The bear case: fluorescence lights up tissue, but does that actually change the operation surgeons perform and improve recurrence-free survival? Only randomized data will answer that.

The intraoperative molecular imaging category is small but has one commercial reference point: Cytalux (pafolacianine, On Target Laboratories), FDA approved in November 2021 for ovarian cancer and expanded to lung cancer in December 2022 [11]. Cytalux targets folate receptor alpha rather than CEA. On Target Laboratories is private and does not disclose revenue publicly; the strongest public signal is a $30 million Series C in November 2023 explicitly earmarked for commercialization, alongside company statements citing more than 1,000 procedures cumulatively by 2025 [16]. A $30M commercialization round three years post-approval, combined with four-figure cumulative case volume, implies the product is running well below blockbuster trajectory and closer to a slow specialty launch. That is the concrete calibration behind the phrase 'modest revenue': not zero, but running years behind what a typical hospital-administered oncology biologic would be doing at this stage. Lumicell's LumiSight was FDA approved in April 2024 for detecting residual cancer in the surgical cavity after breast lumpectomy, using a different chemistry (cathepsin-activated probe) [12]. These agents share SGM-101's core value proposition but target different tumor types. Within colorectal surgery specifically, SGM-101 has no direct approved competitor. Indocyanine green (ICG) is used off-label for perfusion imaging and lymph node visualization but is not tumor-targeted, so it flags any tissue with blood flow rather than specifically identifying cancer cells. The under-discussed adoption gate is OR camera hardware. SGM-101 emits at roughly 700 nm and requires a NIR-capable imaging platform configured for that wavelength range. The installed base is uneven. Stryker's 1688 AIM 4K platform (successor to the SPY/PINPOINT line acquired via Novadaq) supports fluorescence imaging in colorectal ORs; Olympus Visera Elite II with the IR module, Karl Storz Image1 S Rubina, and Intuitive's da Vinci Xi Firefly module all provide NIR fluorescence capability but on excitation and emission characteristics originally tuned for ICG imaging at around 800 nm rather than the 700 nm range where SGM-101 emits [17]. Cytalux's early sales were suppressed in part because compatible NIR camera systems were not standard equipment at many hospitals, and the same headwind will affect SGM-101 unless Surgimab explicitly bundles or certifies compatibility with the platforms most colorectal surgeons already have. No public disclosure describes a Surgimab hardware partnership or bundled access program, and that is a gap. Reimbursement is the other bottleneck. Cytalux's early sales were suppressed by patchy commercial coverage and limited CMS pass-through status (a temporary Medicare payment category that allows hospitals to bill separately for a newly approved drug during the two-to-three-year window before a permanent payment code is established). If the Phase 3 reads out clean and Surgimab or a partner secures a permanent J-code and hospital outpatient pass-through payment, SGM-101 could carve out a defensible niche in the roughly 40,000 annual US rectal cancer resections and roughly 150,000 colorectal resections overall. Surgimab remains a private, capital-constrained French company; total funding raised and current runway are not publicly disclosed in detail, which is itself informative about the near-term commercial resourcing question. Whether Surgimab can execute a Phase 3 readout, BLA filing, and US launch alone, or will need a commercial partner, is the biggest open question for the company's trajectory. Revenue data not available for Surgimab.

SGM-101 is the most biologically rational intraoperative imaging agent for colorectal cancer that exists today. CEA is the right target: it is expressed on the majority of colorectal tumors, it sits on the cell surface where an antibody can reach it, and its expression is high enough above baseline healthy tissue to give a clean fluorescence signal. The Phase 1 and Phase 2 data across colorectal, peritoneal, pancreatic, and lung indications all point in the same direction: the tool works technically [1][2][15]. The unresolved question is whether it works clinically in a way that changes surgical practice and long-term patient outcomes. The Cytalux precedent is the cautionary tale: FDA approval does not equal adoption, and payer coverage plus surgeon workflow plus NIR camera availability all need to click into place before revenue follows. Four things to watch: (1) the Phase 3 NCT03659448 readout, now most plausibly 2027 given ongoing recruitment past the December 2024 estimated completion; (2) any partnership announcement that would give Surgimab US commercial infrastructure and OR camera hardware compatibility programs; (3) EU regulatory progress at EMA and reimbursement decisions at HAS, ZIN, and NICE, which are the more likely near-term milestones for a French company; and (4) CMS pass-through payment decisions for existing intraoperative imaging agents, which would signal a viable US reimbursement path. If most of these break the right way, SGM-101 is a plausible standard-of-care addition to locally advanced and recurrent rectal cancer surgery within four to five years. If they stall, this becomes a niche academic tool used at a handful of European and US centers.

Our model estimates a 14% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 48%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by its light or open-label blinding; it is held back by the sponsor's thin or weak approval record, its few secondary endpoints, and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.